FindTrial
Sign In

Development of anti-2019-nCoV therapeutic antibody from the recovered novel coronavirus pneumonia patients (COVID-19)

Development of 2019-nCoV therapeutic antibody

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000030012
Enrollment
Unknown
Registered
2020-02-19
Start date
2020-02-19
Completion date
Unknown
Last updated
2020-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Case series:NA

Sponsors

The First People's Hospital of Chenzhou, Institute of Translational Medicine,University of South China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1)2019-nCoV-cured patients that over 18 years of age 2)Sign informed consent.

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

MeasureTime frame
NA;—

Countries

China

Contacts

Public ContactXiaoWang Qu

The First People's Hospital of Chenzhou, Institute of Translational Medicine,University of South China

quxiaowang@163.com+86 15526272595

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026